Yaima Luzardo Lightfoot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yaima Luzardo Lightfoot has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- William J. Ray
The University of Texas MD Anderson Cancer Center
2 shared publications - Adrian Beckmann
The University of Texas MD Anderson Cancer Center 3 The Neurodegeneration Consortium, Therapeutics Discovery Division Houston, TX, USA
1 shared publication - Alexandra Botte
The Neurodegeneration Consortium, UT MD Anderson Cancer Center, Houston, TX USA
1 shared publication - Alison E. Mungenast
Picower Institute for Learning and Memory, Massachusetts Institute of Technology 1 Department of Brain and Cognitive Sciences Cambridge, MA, USA
1 shared publication - Alison M. Goate
Icahn School of Medicine at Mount Sinai
1 shared publication - Anne Schaefer
Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, USA
1 shared publication
Latest Publications
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S21)
RIP Kinase 1 (RIPK1) modulates disease associated microglial response during demyelination
Background: RIP Kinase 1 (RIPK1) is known to regulate necroptotic cell death in response to pro‐inflammatory signaling in cells where apoptotic signaling has been compromised. Aberrant RIPK1 activation has been implicated in several neurodegenerative disorders such as Alzheimer’s disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis.Method: To investigate the role of RIPK1 in regulating the microglial response to demyelination, we administered a highly selective CNS penetrant RIPK1 inhibitor to C57Bl6 mice fed with cuprizone. We studied the microglial response using RNA Sequencing, single‐cell RNA Sequencing, lipidomics, and proteomics.Result: Transcriptomic analysis of isolated microglia and brain cytokine levels revealed that rapid demyelination induced by Cuprizone diet led to a strong disease‐associated microglia (DAM) response. Of the 1957 transcripts regulated in isolated microglia (padj<0.05) by the demyelination, RIPK1 inhibition significantly attenuated the microglial transcriptomic response of 497 transcripts (padj<0.1). Single‐cell RNA Sequencing analysis revealed that RIPK1 inhibition modified demyelination‐associated microglial sub‐clusters. Furthermore, soluble TREM2, a marker of microglia activation, was reduced, as were several cytokines in the brain. Open field analysis of these mice showed that RIPK1 inhibition rescued Cuprizone‐induced motor impairment. Proteomics and lipidomics analyses demonstrated RIPK1‐dependent changes in brain lipid metabolism.Conclusion: RIPK1 signaling promotes an inflammatory response that involves modulation of key regulatory pathways associated with demyelinating disorders.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S21)
Open AccessRIP Kinase 1 (RIPK1) modulates disease associated microglial response during demyelination
Background: RIP Kinase 1 (RIPK1) is known to regulate necroptotic cell death in response to pro‐inflammatory signaling in cells where apoptotic signaling has been compromised. Aberrant RIPK1 activation has been implicated in several neurodegenerative disorders such as Alzheimer’s disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis.Method: To investigate the role of RIPK1 in regulating the microglial response to demyelination, we administered a highly selective CNS penetrant RIPK1 inhibitor to C57Bl6 mice fed with cuprizone. We studied the microglial response using RNA Sequencing, single‐cell RNA Sequencing, lipidomics, and proteomics.Result: Transcriptomic analysis of isolated microglia and brain cytokine levels revealed that rapid demyelination induced by Cuprizone diet led to a strong disease‐associated microglia (DAM) response. Of the 1957 transcripts regulated in isolated microglia (padj<0.05) by the demyelination, RIPK1 inhibition significantly attenuated the microglial transcriptomic response of 497 transcripts (padj<0.1). Single‐cell RNA Sequencing analysis revealed that RIPK1 inhibition modified demyelination‐associated microglial sub‐clusters. Furthermore, soluble TREM2, a marker of microglia activation, was reduced, as were several cytokines in the brain. Open field analysis of these mice showed that RIPK1 inhibition rescued Cuprizone‐induced motor impairment. Proteomics and lipidomics analyses demonstrated RIPK1‐dependent changes in brain lipid metabolism.Conclusion: RIPK1 signaling promotes an inflammatory response that involves modulation of key regulatory pathways associated with demyelinating disorders.
- Open Access
- 29 August 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (11)
A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation
Pervasive neuroinflammation occurs in many neurodegenerative diseases, including Alzheimer’s disease (AD). SPI1/PU.1 is a transcription factor located at a genome-wide significant AD-risk locus and its reduced expression is associated with delayed onset of AD. We analyzed single-cell transcriptomic datasets from microglia of human AD patients and found an enrichment of PU.1-binding motifs in the differentially expressed genes. In hippocampal tissues from transgenic mice with neurodegeneration, we found vastly increased genomic PU.1 binding. We then screened for PU.1 inhibitors using a PU.1 reporter cell line and discovered A11, a molecule with anti-inflammatory efficacy and nanomolar potency. A11 regulated genes putatively by recruiting a repressive complex containing MECP2, HDAC1, SIN3A, and DNMT3A to PU.1 motifs, thus representing a novel mechanism and class of molecules. In mouse models of AD, A11 ameliorated neuroinflammation, loss of neuronal integrity, AD pathology, and improved cognitive performance. This study uncovers a novel class of anti-inflammatory molecules with therapeutic potential for neurodegenerative disorders.
- 29 August 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (11)
Open AccessA novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation
Pervasive neuroinflammation occurs in many neurodegenerative diseases, including Alzheimer’s disease (AD). SPI1/PU.1 is a transcription factor located at a genome-wide significant AD-risk locus and its reduced expression is associated with delayed onset of AD. We analyzed single-cell transcriptomic datasets from microglia of human AD patients and found an enrichment of PU.1-binding motifs in the differentially expressed genes. In hippocampal tissues from transgenic mice with neurodegeneration, we found vastly increased genomic PU.1 binding. We then screened for PU.1 inhibitors using a PU.1 reporter cell line and discovered A11, a molecule with anti-inflammatory efficacy and nanomolar potency. A11 regulated genes putatively by recruiting a repressive complex containing MECP2, HDAC1, SIN3A, and DNMT3A to PU.1 motifs, thus representing a novel mechanism and class of molecules. In mouse models of AD, A11 ameliorated neuroinflammation, loss of neuronal integrity, AD pathology, and improved cognitive performance. This study uncovers a novel class of anti-inflammatory molecules with therapeutic potential for neurodegenerative disorders.
- 13 July 2012
- Published by Springer Nature
- Vol. 900, 347-362
Oxidative Stress and Beta Cell Dysfunction
Autoimmune Type 1 A Diabetes (T1D) is characterized by dependence on exogenous insulin consequential to the autoimmune attack and destruction of insulin-producing islet beta cells. Pancreatic islet cell inflammation, or insulitis, precedes beta cell death and T1D onset. In the insulitic lesion, innate immune cells produce chemokines and cytokines that recruit and activate adaptive immune cells (Eizirik D et al., Nat Rev Endocrinol 5:219–226, 2009). Locally produced cytokines not only increase immune surveillance of beta cells (Hanafusa T and Imagawa A, Ann NY Acad Sci 1150:297–299, 2008), but also cause beta cell dysfunction and decreased insulin secretion due to the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) by the beta cells. This, coupled to the high levels of ROS and RNS secreted by activated macrophages and the low antioxidant capacities of beta cells (Huurman VA, PLoS One 3:e2435, 2008; Schatz D, Pediatr Diabetes 5:72–79, 2004; Verge CF, Diabetes 44:1176–1179, 1995), implicates free radicals as important effectors in T1D pathogenesis (Eizirik D et al., Nat Rev Endocrinol 5:219–226, 2009; Hanafusa T and Imagawa A, Ann NY Acad Sci 1150:297–299, 2008; Eisenbarth GS and Jeffrey J, Arq Bras Endocrinol Metabol 52:146–155, 2008; Pietropaolo M et al., Pediatr Diabetes 6:184–192, 2005).
- 13 July 2012
- Published by Springer Nature
- Vol. 900, 347-362
Oxidative Stress and Beta Cell Dysfunction
Autoimmune Type 1 A Diabetes (T1D) is characterized by dependence on exogenous insulin consequential to the autoimmune attack and destruction of insulin-producing islet beta cells. Pancreatic islet cell inflammation, or insulitis, precedes beta cell death and T1D onset. In the insulitic lesion, innate immune cells produce chemokines and cytokines that recruit and activate adaptive immune cells (Eizirik D et al., Nat Rev Endocrinol 5:219–226, 2009). Locally produced cytokines not only increase immune surveillance of beta cells (Hanafusa T and Imagawa A, Ann NY Acad Sci 1150:297–299, 2008), but also cause beta cell dysfunction and decreased insulin secretion due to the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) by the beta cells. This, coupled to the high levels of ROS and RNS secreted by activated macrophages and the low antioxidant capacities of beta cells (Huurman VA, PLoS One 3:e2435, 2008; Schatz D, Pediatr Diabetes 5:72–79, 2004; Verge CF, Diabetes 44:1176–1179, 1995), implicates free radicals as important effectors in T1D pathogenesis (Eizirik D et al., Nat Rev Endocrinol 5:219–226, 2009; Hanafusa T and Imagawa A, Ann NY Acad Sci 1150:297–299, 2008; Eisenbarth GS and Jeffrey J, Arq Bras Endocrinol Metabol 52:146–155, 2008; Pietropaolo M et al., Pediatr Diabetes 6:184–192, 2005).